Licensing

Biocon is continuously leveraging its rich pool of research talent to pursue its mid-to-long-term goals to collaboratively develop MAbs (Monoclonal Antibodies) Human Insulin and their analogs and other novel drug delivery systems-based proteins either in-house or in partnership with other companies. Such symbiotic co-development activities will enable Biocon to out-license the researched product for global markets. As we focus our resources on various R&D programs in key disease segments, we believe out-licensing is the way forward and will be a significant future growth driver for the company.